Marinus Pharmaceuticals (NASDAQ:MRNS) Raised to “Strong-Buy” at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I upgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS) to a strong-buy rating in a report published on Monday, Zacks.com reports.

Other research analysts also recently issued research reports about the company. LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a buy rating to a neutral rating in a research note on Wednesday, August 14th. Truist Financial reiterated a buy rating and set a $10.00 price objective on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. Cantor Fitzgerald restated an overweight rating and issued a $13.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 24th. StockNews.com downgraded shares of Marinus Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, September 26th. Finally, JMP Securities reiterated a market outperform rating and issued a $10.00 price target on shares of Marinus Pharmaceuticals in a research note on Monday, September 23rd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Marinus Pharmaceuticals currently has a consensus rating of Moderate Buy and a consensus target price of $8.83.

Marinus Pharmaceuticals Trading Up 1.8 %

Shares of MRNS stock opened at $1.70 on Monday. The stock has a market cap of $93.39 million, a P/E ratio of -0.64 and a beta of 1.13. Marinus Pharmaceuticals has a 1 year low of $1.05 and a 1 year high of $11.26. The company has a current ratio of 2.28, a quick ratio of 2.15 and a debt-to-equity ratio of 5.68. The stock has a 50 day simple moving average of $1.43 and a 200 day simple moving average of $2.42.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. The firm had revenue of $8.06 million for the quarter, compared to the consensus estimate of $9.05 million. During the same period last year, the company posted ($0.61) EPS. On average, research analysts predict that Marinus Pharmaceuticals will post -1.88 earnings per share for the current fiscal year.

Institutional Trading of Marinus Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in MRNS. Point72 DIFC Ltd bought a new stake in Marinus Pharmaceuticals during the second quarter valued at $28,000. SG Americas Securities LLC acquired a new position in shares of Marinus Pharmaceuticals in the 2nd quarter valued at about $34,000. AQR Capital Management LLC boosted its position in shares of Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Marinus Pharmaceuticals during the second quarter worth approximately $64,000. Finally, Values First Advisors Inc. increased its holdings in Marinus Pharmaceuticals by 501.8% in the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 52,257 shares in the last quarter. 98.80% of the stock is currently owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.